Update on Therapeutic Drug Monitoring in Crohn's Disease

Gastroenterology Clinics of North America

Volumn 46, Issue 3, 2017, Pages 645-659

  Heron, Valérie ^a   Afif, Waqqas ^a  

^a MONTREAL GENERAL HOSPITAL   (Canada)

Author keywords

Anti drug antibodies; Anti tumor necrosis factor; Biologics; Crohn's disease; Drug concentrations; Inflammatory bowel disease; Therapeutic drug monitoring

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; BIOSIMILAR AGENT; DRUG ANTIBODY; INFLIXIMAB; TUMOR NECROSIS FACTOR; USTEKINUMAB; VEDOLIZUMAB; ANTIBODY; IMMUNOSUPPRESSIVE AGENT;

ANTIBODY BLOOD LEVEL; ASSAY; CHEMILUMINESCENCE IMMUNOASSAY; CLINICAL OUTCOME; COST EFFECTIVENESS ANALYSIS; CROHN DISEASE; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MONITORING; ENDOSCOPY; ENZYME LINKED IMMUNOSORBENT ASSAY; HIGH MOBILITY SHIFT ASSAY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MAINTENANCE THERAPY; RADIOIMMUNOASSAY; REMISSION; REVIEW; TREATMENT RESPONSE; ANTAGONISTS AND INHIBITORS; BLOOD; DEPRESCRIPTION; IMMUNOLOGY; MAINTENANCE CHEMOTHERAPY; TREATMENT OUTCOME;

ANTIBODIES; CROHN DISEASE; DEPRESCRIPTIONS; DRUG MONITORING; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MAINTENANCE CHEMOTHERAPY; REMISSION INDUCTION; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 85028646604     PISSN: 08898553     EISSN: 15581942     Source Type: Journal    
DOI: 10.1016/j.gtc.2017.05.014     Document Type: Review

References (72)

1. Colombel, J.F., Sandborn, W.J., Rutgeerts, P., et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 132:1 (2007), 52–65.
2. Chaparro, M.C.A.D., Panes, J., García, V., et al. Long-term durability of infliximab treatment in Crohn's disease and efficacy of dose “escalation” in patients losing response. J Clin Gastroenterol 45:2 (2011), 113–118.
3. Malíčková, K., Ďuricová, D., Bortlík, M., et al. Serum trough infliximab levels: a comparison of three different immunoassays for the monitoring of CT-P13 (infliximab) treatment in patients with inflammatory bowel disease. Biologicals 44:1 (2016), 33–36.
4. Baert, F., Noman, M., Vermeire, S., et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 348:7 (2003), 601–608.
5. Kopylov, U., Mazor, Y., Yavzori, M., et al. Clinical utility of antihuman lambda chain-based enzyme-linked immunosorbent assay (ELISA) versus double antigen ELISA for the detection of anti-infliximab antibodies. Inflamm Bowel Dis 18:9 (2012), 1628–1633.
6. Vaughn, B.P., Sandborn, W.J., Cheifetz, A.S., Biologic concentration testing in inflammatory bowel disease. Inflamm Bowel Dis 21:6 (2015), 1435–1442.
7. Wang, S.L., Ohrmund, L., Hauenstein, S., et al. Development and validation of a homogeneous mobility shift assay for the measurement of infliximab and antibodies-to-infliximab levels in patient serum. J Immunol Methods 382:1–2 (2012), 177–188.
8. Ordás, I., Feagan, B.G., Sandborn, W.J., Therapeutic drug monitoring of tumor necrosis factor antagonists in inflammatory bowel disease. Clin Gastroenterol Hepatol 10:10 (2012), 1079–1087.
9. Blank, M., Black, S., Chun, K., et al. P0942 comparisons of serum infliximab and antibodies-to-infliximab tests used in inflammatory bowel disease clinical trials of remicade. United European Gastroenterol J, 2(Suppl 1), 2015.
10. Steenholdt, C., Ainsworth, M.A., Tovey, M., et al. Comparison of techniques for monitoring infliximab and antibodies against infliximab in Crohn's disease. Ther Drug Monit 35:4 (2013), 530–538.
11. Hoekman, D.R., Lowenberg, M., Mathôt, R.A., et al. 536 non-trough IFX concentrations reliably predict trough levels and accelerate dose-adjustment in Crohn's disease. Gastroenterology, 148(4), 2015, S-107.
12. Stewart, M.J., Dubinsky, M., Morganstern, B., et al. Sa1965 the steady-state pharmacokinetics of adalimumab: do we need to drink from the “trough”?. Gastroenterology 150:4 (2016), S418–S419.
13. Maser, E.A., Villela, R., Silverberg, M.S., et al. Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease. Clin Gastroenterol Hepatol 4:10 (2006), 1248–1254.
14. Bortlik, M., Duricova, D., Malickova, K., et al. Infliximab trough levels may predict sustained response to infliximab in patients with Crohn's disease. J Crohns Colitis 7:9 (2013), 736–743.
15. Roblin, X., Marotte, H., Leclerc, M., et al. Combination of C-reactive protein, infliximab trough levels, and stable but not transient antibodies to infliximab are associated with loss of response to infliximab in inflammatory bowel disease. J Crohns Colitis 9:7 (2015), 525–531.
16. Cornillie, F., Hanauer, S.B., Diamond, R.H., et al. Postinduction serum infliximab trough level and decrease of C-reactive protein level are associated with durable sustained response to infliximab: a retrospective analysis of the ACCENT I trial. Gut 63:11 (2014), 1721–1727.
17. Vande Casteele, N., Khanna, R., Levesque, B.G., et al. The relationship between infliximab concentrations, antibodies to infliximab and disease activity in Crohn's disease. Gut 64:10 (2014), 1539–1545.
18. Karmiris, K., Paintaud, G., Noman, M., et al. Influence of trough serum levels and Immunogenicity on long-term outcome of Adalimumab therapy in Crohn's disease. Gastroenterology 137:5 (2009), 1628–1640.
19. Mazor, Y., Almog, R., Kopylov, U., et al. Adalimumab drug and antibody levels as predictors of clinical and laboratory response in patients with Crohn's disease. Aliment Pharmacol Ther 40:6 (2014), 620–628.
20. Peyrin-Biroulet, L., Sandborn, W., Sands, B.E., et al. Selecting therapeutic targets in inflammatory bowel disease [STRIDE]: determining therapeutic goals for treat-to-target. Am J Gastroenterol 110 (2015), 1324–1338.
21. Paul, S., Tedesco, E.D., Marotte, H., et al. Therapeutic drug monitoring of infliximab and mucosal healing in inflammatory bowel disease. Inflamm Bowel Dis 19:12 (2013), 2568–2576.
22. Roblin, X., Marotte, H., Rinaudo, M., et al. Association between pharmacokinetics of adalimumab and mucosal healing in patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol 12:1 (2014), 80–84.e2.
23. Zittan, E., Kabakchiev, B., Milgrom, R., et al. Higher adalimumab drug levels are associated with mucosal healing in patients with Crohn's disease. J Crohns Colitis 10:5 (2016), 510–515.
24. Ungar, B., Levy, I., Yavne, Y., et al. Optimizing anti-TNF-α therapy: serum levels of infliximab and adalimumab are associated with mucosal healing in patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol 14:4 (2016), 550–557.e2.
25. Colombel, J.F., Sandborn, W.J., Allez, M., et al. Association between plasma concentrations of certolizumab pegol and endoscopic outcomes of patients with Crohn's disease. Clin Gastroenterol Hepatol 12:3 (2014), 423–431.e1.
26. Garcês, S., Demengeot, J., Benito-Garcia, E., The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: a systematic review of the literature with a meta-analysis. Ann Rheum Dis 72:12 (2012), 1947–1955.
27. Baert, F., Kondragunta, V., Lockton, S., et al. Antibodies to adalimumab are associated with future inflammation in Crohn's patients receiving maintenance adalimumab therapy: a post hoc analysis of the Karmiris trial. Gut 65:7 (2015), 1126–1131.
28. Colombel, J.F., Sandborn, W.J., Reinisch, W., et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 362:15 (2010), 1383–1395.
29. Feagan, B.G., Mcdonald, J.W., Panaccione, R., et al. Methotrexate in combination with infliximab is no more effective than infliximab alone in patients with Crohn's disease. Gastroenterology 146:3 (2014), 681–688.e1.
30. Krieckaert, C.L., Nurmohamed, M.T., Wolbink, G.J., Methotrexate reduces immunogenicity in adalimumab treated rheumatoid arthritis patients in a dose dependent manner. Ann Rheum Dis 71:11 (2012), 1914–1915.
31. Jani, M., Barton, A., Warren, R.B., et al. The role of DMARDs in reducing the immunogenicity of TNF inhibitors in chronic inflammatory diseases. Rheumatology 53:2 (2013), 213–222.
32. Herfarth, H.H., Kappelman, M.D., Long, M.D., et al. Use of methotrexate in the treatment of inflammatory bowel diseases. Inflamm Bowel Dis 22:1 (2016), 224–233.
33. Ordás, I., Mould, D.R., Feagan, B.G., et al. Anti-TNF monoclonal antibodies in inflammatory bowel disease: pharmacokinetics-based dosing paradigms. Clin Pharmacol Ther 91:4 (2012), 635–646.
34. Yarur, A.J., Rubin, D.T., Therapeutic drug monitoring of anti-tumor necrosis factor agents in patients with inflammatory bowel diseases. Inflamm Bowel Dis 21:7 (2015), 1709–1718.
35. Ainsworth, M.A., Bendtzen, K., Brynskov, J., Tumor necrosis factor-alpha binding capacity and anti-infliximab antibodies measured by fluid-phase radioimmunoassays as predictors of clinical efficacy of infliximab in Crohn's disease. Am J Gastroenterol 103:4 (2008), 944–948.
36. Ben-Horin, S., Chowers, Y., Review article: loss of response to anti-TNF treatments in Crohn's disease. Aliment Pharmacol Ther 33:9 (2011), 987–995.
37. Afif, W., Loftus, E.V., Faubion, W.A., et al. Clinical utility of measuring Infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease. Am J Gastroenterol 105:5 (2010), 1133–1139.
38. Yanai, H., Lichtenstein, L., Assa, A., et al. Levels of drug and antidrug antibodies are associated with outcome of interventions after loss of response to Infliximab or Adalimumab. Clin Gastroenterol Hepatol 13:3 (2015), 522–530.e2.
39. Yarur, A., Kanagala, V., Stein, D., et al. Higher infliximab trough levels are associated with a higher rate of perianal fistula healing in patients with Crohn's disease. Aliment Pharmacol Ther 45:7 (2017), 933–940.
40. Ungar, B., Chowers, Y., Yavzori, M., et al. The temporal evolution of antidrug antibodies in patients with inflammatory bowel disease treated with infliximab. Gut 63:8 (2013), 1258–1264.
41. Candon, S., Mosca, A., Ruemmele, F., et al. Clinical and biological consequences of immunization to infliximab in pediatric Crohn's disease. Clin Immunol 118:1 (2006), 11–19.
42. Nanda, K.S., Cheifetz, A.S., Moss, A.C., Impact of antibodies to infliximab on clinical outcomes and serum infliximab levels in patients with inflammatory bowel disease (IBD): a meta-analysis. Am J Gastroenterol 108:1 (2012), 40–47.
43. Paul, S., Moreau, A.C., Tedesco, E.D., et al. Pharmacokinetics of adalimumab in inflammatory bowel diseases. Inflamm Bowel Dis 20:7 (2014), 1288–1295.
44. Ruiz-Argüello, B.C.B., Agua, A.R.D., Torres, N., et al. Comparison study of two commercially available methods for the determination of infliximab, adalimumab, etanercept and anti-drug antibody levels. Clin Chem Lab Med 51:12 (2013), e287–e289.
45. Strik, A., Van Den Brink, G., Ponsioen, C., et al. DOP066. Disappearance of anti-drug antibodies to infliximab and adalimumab after addition of an immunomodulator in patients with inflammatory bowel disease. J Crohns Colitis, 10(Suppl 1), 2016.
46. Ben–Horin, S., Waterman, M., Kopylov, U., et al. Addition of an immunomodulator to infliximab therapy eliminates antidrug antibodies in serum and restores clinical response of patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 11:4 (2013), 444–447.
47. Melmed, G.Y., Irving, P.M., Jones, J., et al. Appropriateness of testing for anti–tumor necrosis factor agent and antibody concentrations, and interpretation of results. Clin Gastroenterol Hepatol 14:9 (2016), 1302–1309.
48. Singh, N., Rosenthal, C.J., Melmed, G.Y., et al. Early infliximab trough levels are associated with persistent remission in pediatric patients with inflammatory bowel disease. Inflamm Bowel Dis 20:10 (2014), 1708–1713.
49. Zittan, E., Kelly, O., Kabakchiev, B., et al. Sa1968 post-induction adalimumab drug levels predict clinical and laboratory remission at week 24 in patients with Crohn's disease. Gastroenterology, 150(4), 2016, S419.
50. Chaparro, M., Guerra, I., Iborra, M., et al. 538 correlation between adalimumab serum levels and remission after the induction phase in Crohn's disease patients. Gastroenterology, 148(4), 2015 S-107–8.
51. Vande Casteele, N., Gils, A., Singh, S., et al. Antibody response to Infliximab and its impact on Pharmacokinetics can be transient. Am J Gastroenterol 108:6 (2013), 962–971.
52. Vande Casteele, N., Ferrante, M., Van Assche, G., et al. Trough concentrations of Infliximab guide Dosing for patients with inflammatory bowel disease. Gastroenterology 148:7 (2015), 1320–1329.e3.
53. D'Haens, G., Vermeire, S., Lambrecht, G., et al. OP029. Drug-concentration versus symptom-driven dose adaptation of Infliximab in patients with active Crohn's disease: a prospective, randomised, multicentre trial (Tailorix). J Crohns Colitis, 10(Suppl 1), 2016.
54. Van Assche, G., Magdelaine–Beuzelin, C., D'Haens, G., et al. Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial. Gastroenterology 134:7 (2008), 1861–1868.
55. Drobne, D., Bossuyt, P., Breynaert, C., et al. Withdrawal of immunomodulators after co-treatment does not reduce trough level of Infliximab in patients with Crohn's disease. Clin Gastroenterol Hepatol 13:3 (2015), 514–521.e4.
56. Del Tedesco, E., Paul, S., Marotte, H., et al. OP010. Azathioprine dose reduction in patients with inflammatory bowel disease on combination therapy: a prospective study. J Crohns Colitis, 10(Suppl 1), 2016.
57. Louis, E., Mary, J.Y., Vernier–Massouille, G., et al. Maintenance of remission among patients with Crohn's disease on antimetabolite therapy after infliximab therapy is stopped. Gastroenterology 142:1 (2012), 63–70.e5.
58. Ben-Horin, S., Chowers, Y., Ungar, B., et al. Undetectable anti-TNF drug levels in patients with long-term remission predict successful drug withdrawal. Aliment Pharmacol Ther 42:3 (2015), 356–364.
59. Hanauer, S.B., Feagan, B.G., Lichtenstein, G.R., et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 359:9317 (2002), 1541–1549.
60. Hanauer, S.B., Rutgeerts, P.J., D'Haens, G., et al. Delayed hypersensitivity to infliximab (Remicade) re-infusion after 2-4 year interval without treatment. Gastroenterology, 116, 1999, A731.
61. Ben-Horin, S., Mazor, Y., Yanai, H., et al. The decline of anti-drug antibody titres after discontinuation of anti-TNFs: implications for predicting re-induction outcome in IBD. Aliment Pharmacol Ther 35:6 (2012), 714–722.
62. Baert, F., Drobne, D., Gils, A., et al. Early trough levels and antibodies to infliximab predict safety and success of reinitiation of infliximab therapy. Clin Gastroenterol Hepatol, 12(9), 2014.
63. Steenholdt, C., Brynskov, J., Thomsen, O.Ø., et al. Individualised therapy is more cost-effective than dose intensification in patients with Crohn's disease who lose response to anti-tNF treatment: a randomised, controlled trial. Gut 63:6 (2014), 919–927.
64. Velayos, F.S., Kahn, J.G., Sandborn, W.J., et al. A test-based strategy is more cost effective than empiric dose escalation for patients with Crohn's disease who lose responsiveness to infliximab. Clin Gastroenterol Hepatol 11:6 (2013), 654–666.
65. Devlin, S.M., Bressler, B., Bernstein, C.N., et al. Overview of subsequent entry biologics for the management of inflammatory bowel disease and Canadian Association of Gastroenterology position statement on subsequent entry biologics. Can J Gastroenterol 27:10 (2013), 567–571.
66. Ben-Horin, S., Casteele, N.V., Schreiber, S., et al. Biosimilars in inflammatory bowel disease: facts and fears of extrapolation. Clin Gastroenterol Hepatol 14:12 (2016), 1685–1696.
67. Ben-Horin, S., Yavzori, M., Benhar, I., et al. Cross-immunogenicity: antibodies to infliximab in Remicade-treated patients with IBD similarly recognise the biosimilar Remsima. Gut 65:7 (2015), 1132–1138.
68. U.S. Food and Drug Administration, Department of Health and Human Services. STELARA (ustekinumab) approval letter. 2016. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2016/761044Orig1s000ltr.pdf. Accessed January 22, 2017.
69. Feagan, B.G., Sandborn, W.J., Gaskink, C., et al. Ustekinumab as induction and maintenance therapy for Crohn's disease. N Engl J Med 375 (2016), 1946–1960.
70. Battat, R., Kopylov, U., Bessissow, T., et al. Association Among Ustekinumab Trough Concentrations and Clinical, Biomarker, and Endoscopic Outcomes in Patients With Crohn's Disease. Clin Gastroenterol Hepatol, 2017 [Epub ahead of print].
71. Sandborn, W., Feagan, B., Rutgeerts, P., et al. Vedolizumab as induction and maintenance therapy for Crohn's disease. N Engl J Med 369:8 (2013), 711–721.
72. Schuster, T., Keller, E., Kräuchi, S., et al. P242. Performance of the BÜHLMANN Quantum Blue® Infliximab point-of-care assay dedicated for therapeutic drug monitoring of serum infliximab trough levels. J Crohns Colitis, 10(Suppl 1), 2016.